| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4209 | Pol7001 | Novel macrocycle antibiotic with selective and potent activity against P. aeruginosa |
|
| DCC4210 | Poloppin-ii | Novel modulator of protein-protein interactions of the mitotic polo-like kinases, targeting KRAS mutant xenografts, indicate avenues, acting synergistically with Crizotinib, an inhibitor of the c-MET receptor, against mutant KRAS-expressing cancer cells |
|
| DCC4211 | Poloxipan | Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis |
|
| DCC4212 | Poly(ethyleneimine) Solution | Used for the transfection of a broad variety of cell lines; Antimicrobial; Novel binding agent of diffusive gradients in thin-films (DGT) technique (PEI-DGT) |
|
| DCC4213 | polygonatone D | Novel activator of Adenosine monophosphate (AMP)-activated protein kinase (AMPK) |
|
| DCC4214 | Polymyxin | Antibiotic as a last-line therapy to treat infections caused by these life-threatening 'superbugs' |
|
| DCC4215 | polyphenol 13b | Novel pan-inhibitor of KCa3.1/KCa2 channels |
|
| DCC4216 | Pom2-c-hmbp | Potent Activator of Vγ9Vδ2 T-Lymphocytes; HMBPP ananlog prodrug |
|
| DCC4217 | Ponfibrate | Hypobetalipoproteinemic and Lipid decreasing agent |
|
| DCC4218 | Poziotinib Hydrochloride | Novel pan-human EGF receptor (HER) inhibitor |
|
| DCC4219 | Ppa250 | Novel iNOS homodimerization inhibitor |
|
| DCC4220 | Pparalpha/delta-in-11 | The first reported PPARα/δ dual antagonist |
|
| DCC4221 | Pparalpha/gamma Agonist N15 | Novel dual PPARα/γ agonist, ameliorating insulin resistance and gluconeogenesis in vivo and vitro |
|
| DCC4222 | Ppi Inhibitor-i | Novel inhibitor of protein-protein interaction (PPI), blocking #212121; font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 14px; font-style: no |
|
| DCC4223 | pp-ii-a03 | Novel insulin mimetic |
|
| DCC4224 | Ppi-in-3344 | Novel pan-RAS-effector PPI inhibitor |
|
| DCC4225 | Ppk1-in-17 | Novel PPK1 inhibitor, preventing UTI effectively through the disruption of the PPK1 function |
|
| DCC4226 | Ppk1-in-8 | Novel PPK1 inhibitor, preventing UTI effectively through the disruption of the PPK1 function |
|
| DCC4227 | pppone | Potent and selective antagonist of melanocortin-4 receptor (MC4R) |
|
| DCC4228 | Ppq-581 | Novel anti-influenza agent, interrupting the crucial RNP trafficking, resulting in influenza replication inhibition, preventing virus-induced cytopathic effects |
|
| DCC4229 | Ppt (water-heme Modulator) | Novel Modulator of Water-Heme Interactions in Low-Spin P450 Complexes of CYP2C9d and CYP125A1 |
|
| DCC4230 | Ppxy Budding Inhibitor 4 | Novel inhibitor of budding of mVP40 and eVP40 VLPs, blocking mVP40-795 Nedd4 protein-protein interaction. |
|
| DCC4231 | Ppxy Budding Inhibitor 5 | Specific blocker of the MARV VP40 PPxY-host Nedd4 interaction and subsequent PPxY-dependent egress of MARV VP40 VLPs. |
|
| DCC4232 | Pqa-11 | Novel potent neuroprotectant, inhibiting glutamate-induced cell death, caspase-3 activation, and amyloid β1-42-induced cell death, also suppressing mitogen-activated protein kinase kinase 4 (MKK4) and c-jun N-terminal kinase (JNK) signaling activated by n |
|
| DCC4233 | Pqc-078 | Novel inhibitor of IMPDH enzyme |
|
| DCC4234 | Pqq-tme | Novel human double minute 2 (HDM2) inhibitor |
|
| DCC4235 | Pqsr Antagonist M64 | Quorum sensing modulator as a PqsR antagonist |
|
| DCC4236 | Pradigastat Featured | Pradigastat (LCQ-908) is a potent, selective and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor. Pradigastat has anti-obesity and anti-diabetic effects. |
|
| DCC4237 | Pravadoline Maleate | Inhibitor of prostaglandin (PG) synthesis |
|
| DCC4238 | Prazosin | Inverse agonist at alpha-1 adrenergic receptors |
|
